secwatch.observer — SEC 8-K summary
======================================

Issuer:     Comera Life Sciences Holdings, Inc. (—)
CIK:        0001907685
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0001193125-22-292016
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq warns Comera Life Sciences of MVLS deficiency; 180-day cure period ends May 17, 2023
--------------------------------------------------------------------------------

- MVLS has been below $35M minimum for 30 consecutive business days, violating Nasdaq rule 5550(b)(2).
- Compliance period runs until May 17, 2023; must close at $35M+ for ten consecutive days.
- Alternative: meet minimum stockholders' equity of $2.5M to regain compliance.
- No immediate impact on listing; stock continues trading on Nasdaq Capital Market under CMRA.
- Company will monitor and evaluate options, but delisting risk remains if deficiency not cured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907685/000119312522292016/0001193125-22-292016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907685/000119312522292016/d410213d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer